Testicular cancer

Robert J. Motzer; Neeraj Agarwal; Clair Beard; Graeme B. Bolger; Barry Boston; Michael A. Carducci; Toni K. Choueiri; Robert A. Figlin; Mayer Fishman; Steven L. Hancock; Gary R. Hudes; Eric Jonasch; Anne Kessinger; Timothy M. Kuzel; Paul H. Lange; Ellis G. Levine; Kim A. Margolin; M. Dror Michaelson; Thomas Olencki; Roberto Pili; Bruce G. Redman; Cary N. Robertson; Lawrence H. Schwartz; Joel Sheinfeld; Jue Wang

doi:10.6004/jnccn.2009.0047

Testicular cancer

Robert J. Motzer
, Neeraj Agarwal
, Clair Beard
, Graeme B. Bolger
, Barry Boston
, Michael A. Carducci
, Toni K. Choueiri
, Robert A. Figlin
, Mayer Fishman
, Steven L. Hancock
, Gary R. Hudes
, Eric Jonasch
, Anne Kessinger
, Timothy M. Kuzel
, Paul H. Lange
, Ellis G. Levine
, Kim A. Margolin
, M. Dror Michaelson
, Thomas Olencki
, Roberto Pili

Bruce G. Redman, Cary N. Robertson, Lawrence H. Schwartz, Joel Sheinfeld, Jue Wang

Medicine

Memorial Sloan-Kettering Cancer Center
University of Utah
Dana-Farber/Brigham and Women's Cancer Center
University of Alabama at Birmingham
St. Jude Children Research Hospital
Johns Hopkins University
City of Hope National Med Center
Moffitt Cancer Center
Stanford University
Fox Chase Cancer Center
University of Texas MD Anderson Cancer Center
Nebraska Medicine
Northwestern University
Fred Hutchinson Cancer Research Center
Roswell Park Cancer Institute
Massachusetts General Hospital Cancer Center
Ohio State University
University of Michigan, Ann Arbor
Duke University

Research output: Contribution to journal › Review article › peer-review

105 Scopus citations

Abstract

An estimated 8090 new cases of testicular cancer were diagnosed in the United States in 2008. Although relatively uncommon overall, germ cell tumors (GCTs) constitute the most common solid tumor in men between the ages of 15 and 34 years. The worldwide incidence of these tumors has more than doubled in the past 40 years. More than 90% of patients diagnosed with GCTs are cured, including 70% to 80% of patients with advanced tumors who are treated with chemotherapy. Standard therapy has been established at essentially all stages of management and must be closely followed to ensure the potential for cure. Updates to the 2009 NCCN Guidelines include the addition of doses for single-agent carboplatin for seminoma and changes to category 1 for recommendations on radiotherapy and surveillance.

Original language	English
Pages (from-to)	672-693
Number of pages	22
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	7
Issue number	6
DOIs	https://doi.org/10.6004/jnccn.2009.0047
State	Published - Jun 2009

Keywords

Alpha-fetoprotein
Cisplatin
Germ cell tumors
Human chorionic gonadotropin
Lactate dehydrogenase
NCCN Clinical Practice Guidelines
Nonseminoma
Seminoma
Testicular cancer

Access to Document

10.6004/jnccn.2009.0047

Cite this

Motzer, R. J., Agarwal, N., Beard, C., Bolger, G. B., Boston, B., Carducci, M. A., Choueiri, T. K., Figlin, R. A., Fishman, M., Hancock, S. L., Hudes, G. R., Jonasch, E., Kessinger, A., Kuzel, T. M., Lange, P. H., Levine, E. G., Margolin, K. A., Michaelson, M. D., Olencki, T., ... Wang, J. (2009). Testicular cancer. JNCCN Journal of the National Comprehensive Cancer Network, 7(6), 672-693. https://doi.org/10.6004/jnccn.2009.0047

@article{186d6040c7fb42f1b322d5b20bd155b4,

title = "Testicular cancer",

abstract = "An estimated 8090 new cases of testicular cancer were diagnosed in the United States in 2008. Although relatively uncommon overall, germ cell tumors (GCTs) constitute the most common solid tumor in men between the ages of 15 and 34 years. The worldwide incidence of these tumors has more than doubled in the past 40 years. More than 90\% of patients diagnosed with GCTs are cured, including 70\% to 80\% of patients with advanced tumors who are treated with chemotherapy. Standard therapy has been established at essentially all stages of management and must be closely followed to ensure the potential for cure. Updates to the 2009 NCCN Guidelines include the addition of doses for single-agent carboplatin for seminoma and changes to category 1 for recommendations on radiotherapy and surveillance.",

keywords = "Alpha-fetoprotein, Cisplatin, Germ cell tumors, Human chorionic gonadotropin, Lactate dehydrogenase, NCCN Clinical Practice Guidelines, Nonseminoma, Seminoma, Testicular cancer",

author = "Motzer, \{Robert J.\} and Neeraj Agarwal and Clair Beard and Bolger, \{Graeme B.\} and Barry Boston and Carducci, \{Michael A.\} and Choueiri, \{Toni K.\} and Figlin, \{Robert A.\} and Mayer Fishman and Hancock, \{Steven L.\} and Hudes, \{Gary R.\} and Eric Jonasch and Anne Kessinger and Kuzel, \{Timothy M.\} and Lange, \{Paul H.\} and Levine, \{Ellis G.\} and Margolin, \{Kim A.\} and Michaelson, \{M. Dror\} and Thomas Olencki and Roberto Pili and Redman, \{Bruce G.\} and Robertson, \{Cary N.\} and Schwartz, \{Lawrence H.\} and Joel Sheinfeld and Jue Wang",

year = "2009",

month = jun,

doi = "10.6004/jnccn.2009.0047",

language = "English",

volume = "7",

pages = "672--693",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Harborside Press",

number = "6",

}

Motzer, RJ, Agarwal, N, Beard, C, Bolger, GB, Boston, B, Carducci, MA, Choueiri, TK, Figlin, RA, Fishman, M, Hancock, SL, Hudes, GR, Jonasch, E, Kessinger, A, Kuzel, TM, Lange, PH, Levine, EG, Margolin, KA, Michaelson, MD, Olencki, T, Pili, R, Redman, BG, Robertson, CN, Schwartz, LH, Sheinfeld, J & Wang, J 2009, 'Testicular cancer', JNCCN Journal of the National Comprehensive Cancer Network, vol. 7, no. 6, pp. 672-693. https://doi.org/10.6004/jnccn.2009.0047

TY - JOUR

T1 - Testicular cancer

AU - Motzer, Robert J.

AU - Agarwal, Neeraj

AU - Beard, Clair

AU - Bolger, Graeme B.

AU - Boston, Barry

AU - Carducci, Michael A.

AU - Choueiri, Toni K.

AU - Figlin, Robert A.

AU - Fishman, Mayer

AU - Hancock, Steven L.

AU - Hudes, Gary R.

AU - Jonasch, Eric

AU - Kessinger, Anne

AU - Kuzel, Timothy M.

AU - Lange, Paul H.

AU - Levine, Ellis G.

AU - Margolin, Kim A.

AU - Michaelson, M. Dror

AU - Olencki, Thomas

AU - Pili, Roberto

AU - Redman, Bruce G.

AU - Robertson, Cary N.

AU - Schwartz, Lawrence H.

AU - Sheinfeld, Joel

AU - Wang, Jue

PY - 2009/6

Y1 - 2009/6

N2 - An estimated 8090 new cases of testicular cancer were diagnosed in the United States in 2008. Although relatively uncommon overall, germ cell tumors (GCTs) constitute the most common solid tumor in men between the ages of 15 and 34 years. The worldwide incidence of these tumors has more than doubled in the past 40 years. More than 90% of patients diagnosed with GCTs are cured, including 70% to 80% of patients with advanced tumors who are treated with chemotherapy. Standard therapy has been established at essentially all stages of management and must be closely followed to ensure the potential for cure. Updates to the 2009 NCCN Guidelines include the addition of doses for single-agent carboplatin for seminoma and changes to category 1 for recommendations on radiotherapy and surveillance.

AB - An estimated 8090 new cases of testicular cancer were diagnosed in the United States in 2008. Although relatively uncommon overall, germ cell tumors (GCTs) constitute the most common solid tumor in men between the ages of 15 and 34 years. The worldwide incidence of these tumors has more than doubled in the past 40 years. More than 90% of patients diagnosed with GCTs are cured, including 70% to 80% of patients with advanced tumors who are treated with chemotherapy. Standard therapy has been established at essentially all stages of management and must be closely followed to ensure the potential for cure. Updates to the 2009 NCCN Guidelines include the addition of doses for single-agent carboplatin for seminoma and changes to category 1 for recommendations on radiotherapy and surveillance.

KW - Alpha-fetoprotein

KW - Cisplatin

KW - Germ cell tumors

KW - Human chorionic gonadotropin

KW - Lactate dehydrogenase

KW - NCCN Clinical Practice Guidelines

KW - Nonseminoma

KW - Seminoma

KW - Testicular cancer

UR - https://www.scopus.com/pages/publications/67651235907

U2 - 10.6004/jnccn.2009.0047

DO - 10.6004/jnccn.2009.0047

M3 - Review article

C2 - 19555582

AN - SCOPUS:67651235907

SN - 1540-1405

VL - 7

SP - 672

EP - 693

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 6

ER -

Testicular cancer

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this